Cann Group has completed its first shipment of medicinal cannabis oil to UK distribution partner Astral Health (part of the LYPHE Group), to be supplied as part of LYPHE’s participation in Project Twenty21, Europe’s largest medicinal cannabis recruitment registry.
Project Twenty21 is a patient registry providing access to medical cannabis while simultaneously gathering data on treatment efficacy. Launched in November 2019, it is the largest medicinal cannabis recruitment initiative in Europe with more than 8,000 patients enrolled through clinics and independent prescribers.
It aims to recruit up to 20,000 medicinal cannabis patients by the end of 2021.
Cann is the exclusive oil supplier to LYPHE within the Project Twenty21 program, after
entering into a five-year supply agreement with Astral Health in May this year.
Cann Group chief operating officer Shane Duncan said Cann had secured the required
regulatory approvals and permits to facilitate the first shipment of its products to
LYPHE. Products should be available for UK doctors to prescribe from next week.
He added: “It is an exciting step forward to get this first shipment off to support such a significant initiative in the UK, which helps position Cann as a leading supplier of medical cannabis in international markets that are continuing to gain momentum.”